BJ Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism. Pharmacoeconomics.
1997;1217- 29Link to Article
RL Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism. Drugs.
2000;60575- 595Link to Article
SC Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet.
1960;11309- 1312Link to Article
Not Available, Prevention of fatal postoperative pulmonary embolism by low doses of heparin: an international multicentre trial. Lancet. 1975;245- 51
R Management of heparin therapy: controlled prospective trial. N Engl J Med.
1975;2921046- 1050Link to Article
A Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet.
1986;21293- 1296Link to Article
et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med.
1990;3221260- 1264Link to Article
European Fraxiparin Study (EFS) Group, Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg.
1988;751058- 1063Link to Article
et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med.
1992;326975- 982Link to Article
et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet.
1992;339441- 445Link to Article
B Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement: comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am. 1991;73484- 493
et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med.
1993;3291370- 1376Link to Article
J Anticoagulants and spinal-epidural anesthesia. Anesth Analg.
1994;791165- 1177Link to Article
et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med.
1996;334677- 681Link to Article
et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med.
1996;334682- 687Link to Article
A Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;791- 7
MRfor the PENTATHLON 2000 Study Steering Committee, Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet.
2002;3591721- 1726Link to Article
AGGfor the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee, Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet.
2002;3591715- 1720Link to Article
AGGfor the Steering Committee of the Pentasaccharide in Major Knee Surgery Study, Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med.
2001;3451305- 1310Link to Article
AGGfor the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study, Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med.
2001;3451298- 1304Link to Article
G High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest.
1999;116903- 908Link to Article
et al. Prevention of venous thromboembolism. Chest.
2001;119(suppl)132S- 175SLink to Article
JH A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000;82929- 938
SA Venous thromboembolic disease after hip surgery: risk factors, prophylaxis, and diagnosis. Clin Orthop. 1989;242212- 231
BF Venous thromboembolism associated with hip and knee arthroplasty: current prophylactic practices and outcomes. Mayo Clin Proc.
1992;67861- 870Link to Article
et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am.
1999;81932- 940Link to Article
W Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med.
1998;1581525- 1531Link to Article
JS The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity anthroplasty: a cohort study of 1,984 patients. Chest.
1998;114(suppl)115S- 118SLink to Article
Pulmonary Embolism Prevention (PEP) Trial Collaborative Group, Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet.
2000;3551295- 1302Link to Article
DJ Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Thromb Haemost. 2001;85940- 941
et al. Prospective study on the usefulness of lung scan in patients with deep vein thrombosis of the lower limbs. Thromb Haemost. 2001;85771- 774
JSfor the Canadian Collaborative Group, The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Arch Intern Med.
1998;158873- 878Link to Article
JF Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med. 1989;82203- 205
MB Natural history of postoperative deep-vein thrombosis. Lancet.
1969;2230- 232Link to Article
DE The value of duplex ultrasound in the follow-up of acute calf vein thrombosis. Int Angiol. 1997;16142- 146
DM Calf deep venous thrombosis: a wolf in sheep's clothing? Arch Intern Med.
1988;1482131- 2138Link to Article
M Total hip replacement and deep vein thrombosis: a venographic and necropsy study. J Bone Joint Surg Br. 1990;729- 13
CW Embolic complications of calf thrombosis following total hip arthroplasty. J Arthroplasty.
1993;8449- 457Link to Article
WH Cost-effectiveness of prophylaxis in total hip replacement. Am J Surg.
1991;161519- 524Link to Article
GC Death and thromboembolic disease after total hip replacement: a series of 1162 cases with no routine chemical prophylaxis. J Bone Joint Surg Br. 1995;776- 10
J Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. Clin Orthop. 1977;127123- 132
CJK Thromboprophylaxis and death after total hip replacement. J Bone Joint Surg Br.
1996;78863- 870Link to Article
R Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med.
1988;3181162- 1173Link to Article
et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am. 1997;79326- 333
et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med.
1997;3371329- 1335Link to Article
et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet.
1992;340152- 156Link to Article
SD Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty: a meta-analysis of randomized trials. Thromb Haemost. 1998;79902- 906
R Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials. Haemostasis. 1997;2775- 84
CR Spinal epidural hematoma due to heparin. Arch Neurol.
1978;35693- 694Link to Article
et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med.
1991;114545- 551Link to Article
et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost. 1988;60407- 410
AM Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med.
1999;130789- 799Link to Article
G A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med.
2000;160181- 188Link to Article
SM Propagation of deep venous thrombosis identified by duplex ultrasonography. J Vasc Surg.
1990;12467- 474Link to Article
BC Thrombus regression in deep venous thrombosis: quantification of spontaneous thrombolysis with duplex scanning. Circulation.
1992;86414- 419Link to Article
et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med. 1977;891018- 1029
HKfor the Certoparin-Study Group, Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Int Angiol. 1998;17135- 145
CM Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin. Semin Thromb Hemost.
2001;27513- 518Link to Article
VVfor the CORTES Investigators, Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med.
2001;344626- 631Link to Article
A Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis: an updated meta-analysis. Drugs.
1996;52Suppl 730- 37Link to Article
J Clot-bound thrombin is protected from inhibition by heparin–antithrombin III but is susceptible to inactivation by antithrombin III–independent inhibitors. J Clin Invest.
1990;86385- 391Link to Article
K Characterization of the binding of factor Xa to fibrinogen/fibrin derivatives and localization of the factor Xa binding site on fibrinogen. Eur J Biochem.
1995;23290- 97Link to Article
PR Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation.
1995;92962- 967Link to Article
JP Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest.
1993;911877- 1883Link to Article
JM Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther. 1997;28316- 22
S The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med.
1993;119874- 881Link to Article
et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med.
1986;3151109- 1114Link to Article
KA Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med.
1997;1572562- 2568Link to Article
et al. Recurrent venous thrombosis and heparin therapy. Arch Intern Med.
1999;1592029- 2032Link to Article
P Pharmacokinetics of heparin and low molecular weight heparin. Baillieres Clin Haematol.
1990;3531- 544Link to Article
et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest.
2001;119(suppl)64S- 94SLink to Article
A Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26(suppl 2)24- 38
et al. Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation.
1994;902385- 2389Link to Article
et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med.
2001;1612215- 2221Link to Article
et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med.
2002;137648- 655Link to Article
et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost. 2003;89288- 296
et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. Thromb Haemost. 2002;87231- 237
J Specific factor Xa inhibitors. Verstraete
EJeds.Cardiovascular Thrombosis Thrombocardiology and Thromboneurology 2nd ed. Philadelphia, Pa Lippincott-Raven1998;173- 188
Y YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. Eur J Pharmacol.
1997;339141- 146Link to Article
et al. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clin Pharmacol Ther.
1999;66258- 264Link to Article
GJ Isolation and characterization of antistasin: an inhibitor of metastasis and coagulation. J Biol Chem. 1987;2629718- 9723
GP Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost. 1993;70212- 216
G Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun.
1983;116492- 499Link to Article
et al. Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin III. Carbohydr Res.
1984;132C5- C9Link to Article
et al. Synthesis of a pentasaccharide corresponding to the antithrombin III binding fragment of heparin. J Carbohydr Chem.
1985;4293- 321Link to Article
M The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew Chem Int Ed Engl.
1993;321671- 1690Link to Article
J In vitro protein binding of Org31540/SR90107A in human plasma and purified antithrombin III [abstract P3095]. Thromb Haemost. July2001;suppl.CD-ROM published by Excerpta Medica Medical Communications.
TE Heparin-induced thrombocytopenia: a clinicopathologic syndrome. Thromb Haemost. 1999;82439- 447
et al. Pharmacokinetics of the natural pentasaccharide (SR 90107A/ORG 31540) with high affinity for antithrombin III following subcutaneous administration in man [abstract 406]. Thromb Haemost. 1993;69655
R Pharmacokinetics of Org31540/SR90107A in young and elderly healthy subjects: a highly favourable pharmacokinetic profile [abstract P3094]. Thromb Haemost. July2001;suppl.CD-ROM published by Excerpta Medica Medical Communications.
JAfor the Pentasaccharide Investigators, A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med.
2001;344619- 625Link to Article
AGG Overview of the clinical results of pentasaccharide in major orthopedic surgery. Haematologica. 2001;86(suppl 11)59- 62
MR Effect on efficacy and safety of the timing of the first pentasaccharide (fondaparinux, Arixtra) administration in the prevention of venous thromboembolism (VTE) after major orthopedic surgery [abstract]. Blood.
2001;98266aLink to Article
et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am. 2001;83900- 906
The Rembrandt Investigators, Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti–factor Xa activity: a phase II evaluation. Circulation.
2000;1022726- 2731Link to Article
PE Inherent flexibility in a potent inhibitor of blood coagulation, recombinant nematode anticoagulant protein c2. Eur J Biochem.
1999;265539- 548Link to Article
J New anticoagulant drugs. Chest.
2001;119(suppl)95S- 107SLink to Article
RA Oral delivery of heparin in combination with sodium N
-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacological considerations. Pharm Res.
1997;141830- 1834Link to Article